akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Tuesday, June 28, 2016

Company News: Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections

- Last patient enrolled in prospective arm of IVD trial

- More than 2,250 prospective and retrospective samples enrolled in study

- Data to be complemented with up to 500 additional contrived samples with focus on rare pathogens

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the completion of patient enrollment in its Unyvero U.S. FDA trial. The primary endpoint of the prospective and retrospective study is the performance of the Unyvero LRT55 Lower Respiratory Tract cartridge in detecting lower respiratory tract infections as compared to microbiology culture, the current diagnostic standard of care.

Friday, June 17, 2016

Company News: Curetis Reports Results of the Annual Shareholder Meeting Held on June 16, 2016

- Dr. Prabhavathi Fernandes elected as member of the Supervisory Board

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 16, 2016.

The shareholders approved all items on the agenda of the AGM, including the election of Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC, USA) as a member of Curetis┬┤ Supervisory Board for a three-year term until 2019. Prabhavathi Fernandes has profound knowledge in infectious diseases and antibiotics as well as experience in successfully founding, building up and leading several biotech companies and taking one public on Nasdaq raising more than half a billion dollars.